Thromboembolism in Medical Technology

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... as venous thromboembolism. "Venous thromboembolism is a serious public health problem that affects ... to that of the placebo group. Venous thromboembolism occurred 11 times in both the nadroparin and ... with idraparinux. Rates of recurrent venous thromboembolism (2.3 percent versus 3.2 percent) and fatal or ...

New Study Suggests Rx Estrogen Delivery Through the Skin May Show Safety Benefits as Opposed to Oral Delivery

... therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to ... that oral, not transdermal estrogen may increase the risk of venous thromboembolism in postmenopausal women." Transdermal estrogen therapies available by ...

Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home

... physicians in achieving better outcomes for AF, venous thromboembolism patients INDIANAPOLIS, March 19 /PRNewswire/ -- Medicare Part B will now ... one-third reduction in death from all causes. The study also showed that thromboembolism was decreased by 55 percent and major hemorrhage was also decreased.(1) ...

Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)

... hospitals in an effort to improve quality and reduce costs. About Venous thromboembolism (VTE) Venous thromboembolism is a general term used to describe the formation of a blood clot ...

Value of Genetic Testing for Preventing Blood Clots Unproven, According to New AHRQ Study

... and utility of genetic tests for FVL and prothrombin G20210A. This report, titled Outcomes of Genetic Testing in Adults with a History of Venous thromboembolism , is the fifth evidence report requested for EGAPP. The authors, who were led by Jodi Segal, M.D., of the AHRQ-supported Johns Hopkins ...

CRESTOR(R) Reduced Risk of Blood Clots in the Veins

... -- A new analysis from the JUPITER study shows that CRESTOR(R) (rosuvastatin calcium) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p =0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive ...

Dronedarone (Multaq(R)) Reduced the Incidence and Duration of Hospitalization in Patients with Atrial Fibrillation

... CV morbidity and mortality(7). The aims of treatment for patients with AF are related to managing the arrhythmia itself and to the prevention of thromboembolism (obstruction of a blood vessel caused by fragments of a blood clot carried from the site of origin to obstruct another vessel). Atrial fibrillation ...

Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b

... Congress of the European Society of Cardiology showed that the investigational oral Factor Xa inhibitor DU-176b reduced the incidence of venous thromboembolism (VTE) compared with dalteparin among patients undergoing elective unilateral hip replacement surgery. There was a statistically significant dose ...

Portola Completes $60 Million Financing to Advance Its Therapeutic Programs

... successfully completed a Phase 2 trial demonstrating betrixaban's proof of clinical concept and a favorable tolerability profile in preventing venous thromboembolism in patients undergoing knee replacement surgery. Later this year, Portola will initiate a Phase 2 clinical study in 500 patients comparing the safety ...

Soliris(R) Improved Fatigue Independent of Changes in Anemia in Patients with PNH by Controlling Hemolysis

... nocturnal hemoglobinuria. Blood. 2005;106:3699-3709. (5) Hillmen P, Muus P, Duhrsen U et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007; 100:4123-4128. (6)Hillmen P, Young NS, Schubert J et al. The complement ...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

... included neutropenia, somnolence and constipation. The Thalidomide combination was also associated with a 5-10% greater risk of Grade 3 and 4 venous thromboembolism and peripheral neuropathy. "Our study results demonstrate the profound impact on overall survival that the addition of Thalidomide to the standard ...

Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study

... (4 percent) for prescription medications. The results of clinical trials evaluating the use of dabigatran etexilate in the prevention of venous thromboembolism following total knee replacement and hip replacement surgery have already been published and an application for registration in Europe was submitted ...

Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation

... than 2 million adults in the U.S. This common sustained cardiac rhythm disorder is associated with substantial mortality and morbidity from stroke, thromboembolism and heart failure. About Solvay Pharmaceuticals, Inc. Solvay Pharmaceuticals, Inc., of Marietta, Georgia, is the U.S. subsidiary of Solvay ...

FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women

... in the Contraindications and Warnings & Precautions sections of the prior label. It emphasizes that women with an active or past history of venous thromboembolism should not take EVISTA and that women at risk for stroke should receive EVISTA only after evaluating the risk-benefit balance with their healthcare ...

The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor

... inhibitor, dabigatran etexilate, administered for a median of 33 days, were non-inferior to injectable enoxaparin in reducing the risk of venous thromboembolism (VTE) after total hip replacement surgery with similar safety. The primary endpoint of this trial was a composite consisting of total venous ...

PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials

... this new analysis has on treatment of patients with PNH." Clinical Data The publication, titled "Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria," analyzed data from 195 patients studied in the Soliris Phase II and Phase III trials, ...

The Lancet Publishes PREVAIL Study Results Showing Lovenox Superiority Over Unfractionated Heparin for Reducing the Risk of Venous ThromboEmbolism in Patients With Acute Ischemic Stroke

... Risk of Having a Venous thromboembolism (VTE) is Reduced by a Significant 43% in Acute ... preferable to unfractionated heparin for venous thromboembolism prophylaxis in this high- risk medically ill ... bleeding and all-cause mortality. About Venous thromboembolism (VTE) ...

New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility

... statistically significant 44% reduction in venous thromboembolism (VTE) events (Deep Vein Thrombosis and / ... (28 plus or minus 4 days) venous thromboembolism (VTE) prophylaxis with enoxaparin, ... the same period. About venous thromboembolism (VTE) ...

International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis

... Appropriate prophylaxis to Prevent VTE Venous thromboembolism (VTE) risk is high among hospital patients and ... for the Evaluation of Patients at Risk for Venous thromboembolism in the Acute Hospital Care Setting) study ... prophylaxis to prevent VTE." About venous thromboembolism (VTE) ...

Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis

... for an average of 33 days, in preventing venous thromboembolism (VTE) and all-cause mortality after total hip ... effective and safe for prevention of major venous thromboembolism following orthopaedic surgery. Abstract presented ... is Effective and Safe in Preventing Venous thromboembolism after Total Knee Replacement Surgery ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head ... RECORD2 are expected to be available by H2 2007. Unmet Needs in Venous thromboembolism (VTE) VTE is a type of thromboembolic disease that affects approximately ...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

... (Xarelto®) achieved superior efficacy in the prevention of venous thromboembolism (VTE) in patients undergoing knee replacement surgery in a head-to-head ... are expected to be available during H2 2007. Unmet Needs in Venous thromboembolism (VTE) VTE is a type of thromboembolic disease that affects approximately ....

Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology

... two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation, and for secondary prevention of myocardial infarction (MI) and ...

Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery

... two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and ...

Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

... two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and ...

Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis

... two clinical stage antithrombotics. Portola's lead compound, PRT054021, is an oral Factor Xa inhibitor for the prevention of venous thromboembolism after orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for secondary prevention of myocardial infarction (MI) and ...